Mp11-09 Incidence of Sexually Transmitted Infections Post-Gender Affirming Vaginoplasty

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia (MP11)1 May 2024MP11-09 INCIDENCE OF SEXUALLY TRANSMITTED INFECTIONS POST-GENDER AFFIRMING VAGINOPLASTY Sophia L. Friedl, Taylor N. Whitt, David Gilbert, and Kirtishri Mishra Sophia L. FriedlSophia L. Friedl , Taylor N. WhittTaylor N. Whitt , David GilbertDavid Gilbert , and Kirtishri MishraKirtishri Mishra View All Author Informationhttps://doi.org/10.1097/01.JU.0001008564.85995.11.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: While individual case reports have demonstrated that sexually transmitted infections (STI) of the neovagina are possible, little is known about the incidence of STIs post-gender affirming vaginoplasty (GAVP). The goal of this study is to quantify the rates of STIs post-GAVP. METHODS: The TriNetX (TriNetX, Inc., Cambridge, MA, USA) database, a clinical research platform that collects electronic health record data, was used to identify adults who underwent GAVP between Jan. 1, 2003 and Nov. 1, 2023. These patients were age matched with cis female adults who had a healthcare visit within the same time period. Outcomes were ≥1 instance of an STI from 3-60 months post-GAVP or index visit. STIs included [chlamydia, gonorrhea, herpes simplex 1 & 2 (HSV), human papillomavirus (HPV), and human immunodeficiency virus (HIV)] were identified using ICD-10 codes. Outcomes were assessed with Kaplan Meier and Hazard Ratios (HR) to determine significance (p<0.05). RESULTS: 6,191 patients (mean age at GAVP 36.4, SD 14.6) who underwent GAVP were age-matched with cis women, revealing significant increased hazard of contracting HPV (HR 2.90 95% CI: 1.70-4.94) and HIV (HR 61.00 95% CI: 8.42-441.9) in the entire cohort. In the 18-39 year old cohort, post-GAVP patients had significantly increased hazard of developing gonorrhea (HR 2.01 95% CI: 1.06-3.82), HPV (HR 2.12 95% CI: 1.18-3.79), and HIV (HR 14.05 95% CI: 4.30-45.91). CONCLUSIONS: Post-GAVP patients have a similar risk of developing chlamydia and HSV, but have increased risk for developing HPV, HIV, and gonorrhea (aged 18-39) compared to cis women. These findings indicate post-GAVP patients are still at risk of contracting STIs, including through their neovaginas, and must be counseled about this possibility. As patients transition and receive GAVP, they remain at high risk for HIV and should continue to be tested as needed. Additionally, providers must become clinically competent at eliciting sexual history and collecting STI samples from neovaginas as more patients receive GAVP. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e153 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sophia L. Friedl More articles by this author Taylor N. Whitt More articles by this author David Gilbert More articles by this author Kirtishri Mishra More articles by this author Expand All Advertisement PDF downloadLoading ...